BioCryst Pharma (BCRX) Commences Public Offering of Common Stock and Pre-Funded Warrants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Call Buying Activity Continues in BioCryst Pharma (BCRX), Targeting Upside in Shares Through July -Susquehanna
May 28, 2020 3:01 PM EDTSusquehanna options strategist Alison Edwards notes call buying activity in BioCryst Pharma (NASDAQ: BCRX), as investors bought ~12k July 9 calls, adding to roughly 20K of the calls bought since early last week. A position of about 30k calls gives investors the right... More
BioCryst Pharma (BCRX) Prices 18.7M Share Common Offering at $4.50/Sh; Announces Pricing of Pre-Funded Warrants Offering
May 28, 2020 5:51 AM EDTBioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 18,711,113 shares of its common stock, offered at a price to the public of $4.50 per share. In addition, and in lieu of common stock, BioCryst is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of... More
